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Abstract
Purpose The great spatial and temporal resolution of positron
emission tomography might provide the answer for patients
with primary hyperparathyroidism (pHPT) and non-localized
parathyroid glands. We performed a systematic review of the
evidence regarding all investigated tracers.
Methods A study was considered eligible when the following
criteria were met: (1) adults ≥17 years old with non-familial
pHPT, (2) evaluation of at least one PET isotope, and (3) post-
surgical and pathological diagnosis as the gold standard.
Performance was expressed in sensitivity and PPV.
Results Twenty-four papers were included subdivided by ra-
diopharmaceutical: 14 studies investigated L-[11C]Methionine
(11C-MET), one [11C]2-hydroxy-N,N,N-trimethylethanamium
(11C-CH), six 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG),
one 6-[18F] fluoro-L-DOPA (18F-DOPA), and three
N-[(18F)Fluoromethyl]-2-hydroxy-N,N-dimethylethanaminium
(18F-FCH). The 14 studies investigating MET included a total
of 327 patients with 364 lesions. Sensitivity for the detection of
a lesion in the correct quadrant had a pooled estimate of 69 %
(95 % CI 60–78 %). Heterogeneity was overall high with I2 of
51 % (p=0.01) for all 14 studies. Pooled PPV ranged from 91
to 100 % with a pooled estimate of 98 % (95 % CI 96–100 %).
Of the other investigated tracers, 18-FCH seems themost prom-
ising with high diagnostic performance.
Conclusions The results of our meta-analysis show that 11C-
MET PET has an overall good sensitivity and PPVandmay be
considered a reliable second-line imaging modality to enable
minimally invasive parathyroidectomy. Our literature review
suggests that 18F-FCH PET may produce even greater accu-
racy and should be further investigated using both low-dose
CT and MRI for anatomical correlation.
Keywords Primary hyperparathyroidism .Minimal invasive
parathyroidectomy . PET/CT . 11C-Methionine .
18F-Fluorocholine
Introduction
Primary hyperparathyroidism (pHPT) is the third most com-
mon endocrine disorder with a prevalence of around 4 per
1000. Incidence rises with age and is twice as common in
women. Patients can present with a wide variety of well-
described symptoms, ranging from nausea and fatigue to se-
vere osteoporosis and cardiovascular complications [1].
Diagnosis is established biochemically, with the finding of
relatively elevated serum calcium (Ca) level and concomitant
inappropriately elevated parathyroid hormone (PTH) level.
Most commonly, only one of the four glands is abnormal—
typically an adenoma—and causes the condition (75–85 %).
Less frequently, there are multiple adenomas (15–25 %) and
very rarely a carcinoma (1 %) [2]. There is a universal
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agreement that all patients with symptoms, significant signs of
disease (renal or bone manifestations), or young age
(<50 years) should undergo surgical exploration [3]. Over
the past decade, there has been a shift towards minimally
invasive parathyroidectomy (MIP); a focused operation
whereby only one parathyroid is removed. Compared to the
conventional neck exploration, in which all four glands are
investigated intra-operatively, MIP is associated with shorter
operating time, lower complication rates, and smaller incision
size [4, 5].
Imaging is critical in order to enable successful MIP. Aside
from its ability to localize the pathological gland(s), accurate
imaging provides valuable anatomical information for the sur-
geon. 99Tc-sestamibi single photon emission computed to-
mography (SPECT-CT) has become one of the mainstays in
first-line parathyroid imaging based on robust evidence dem-
onstrating its ability to predict the location of an adenoma [6].
However, a recent meta-analysis showed that its sensitivity is
only 63–84 % (depending on protocol), which leaves a sub-
stantial amount of cases with equivocal imaging results [7].
For these cases, several second-line imaging modalities like
MRI and CTare used, which have variable performance char-
acteristics. Another modality that has been studied is positron
emission tomography (PET). The greater spatial and temporal
resolution of PET compared to SPECT imaging allows detec-
tion of even the smallest pathological glands, which in theory
could improve sensitivity. One of the first reported uses of
PET for parathyroid disease used 2-deoxy-2-[18F]fluoro-D-
glucose (18F-FDG), which revealed the location of a patho-
logical parathyroid gland in a patient with pHPT [8]. Over the
years, several other tracers have been investigated as well,
with variable results. The performance of PET depends mostly
on the ability of the tracer to show specific uptake in the
targeted organ. Although PET seems to be a promising new
possibility for imaging of pathologic parathyroid glands, not
all radiopharmaceuticals are suitable based on multiple fac-
tors, including tracer half-life, specificity to parathyroid up-
take, and individual hospital characteristics. To our knowl-
edge, there is no pre-existing literature that has reviewed all
of the investigated PET tracers in patients with pHPT.
Therefore, we performed a systematic review of the evidence
available regarding all investigated tracers and also performed
a meta-analysis of the data regarding the use of
L-(11C)Methionine (11C-MET), the most extensively investi-
gated tracer thus far.
Material and methods
Literature search
We performed a search of the Embase, PubMed, and
Cochrane Library databases published through March 18,
2016, to identify studies investigating the diagnostic value
of all PET radiopharmaceuticals for parathyroid localiza-
tion in patients with biochemical pHPT. We employed an
extensive search filter by using all relevant synonyms and
Mesh/Emtree terms (Table 1). We completed our search
by performing a robust cross-reference check in Web of
Science and manually searched references of selected ar-
ticles, related reviews, and guidelines.
Inclusion and exclusion criteria
From the publications retrieved via our systematic search,
we removed any duplicates (Fig. 1). All remaining unique
publications were screened based on title and abstract for
eligibility. A study was considered eligible when the fol-
lowing criteria were met: (1) adults ≥17 years old with
biochemical non-familial pHPT, (2) evaluation of at least
one PET tracer, and (3) post-surgical and pathological
diagnosis as the gold standard. If an article presented data
for multiple study groups, of which some were eligible for
inclusion, the eligible study groups were included if their
pertinent data could be extracted.
We excluded studies that differed in design (case reports,
systematic reviews), domain (other than pHPT), and language
(non-English). All titles and abstracts were screened




PubMed and Cochrane database
Patient
1 Hyperparathyroidism OR parathyroid OR HPT
OR PHPT
2 MeSH descriptor hyperparathyroidism explode
all trees
Intervention
3 PET OR BPositron Emission Tomography^
4 MeSH descriptor Tomography, Emission-
Computed explode all trees
Embase
Patient
1 Hyperparathyroidism OR parathyroid OR HPT
OR PHPT
2 EMTREE hyperparathyroidism explosion
Intervention
3 PET OR BPositron Emission Tomography^
4 EMTREE positron emission tomography
explosion
Merge
5 1 OR 2
6 3 OR 4
7 5 AND 6
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independently by two authors (W.P.K. and J.D.P.). Any dis-
agreements in selection were discussed, and after consensus,
the selected papers were screened for full text review.
Studies were included in the systematic review if they in-
vestigated at least five patients, independent of the tracer.
Studies were included in the meta-analysis if the following
inclusion criteria were met: (1) use of the tracer 11C-MET,
(2) extractable and unique data for the calculation of sensitiv-
ity and PPV for localization of pathological gland(s) to the
correct quadrant (left lower, right lower, left upper, right up-
per, or ectopic), (3) histological examination of the resected
parathyroid gland(s), and (4) a minimum of five included
patients.
Quality assessment
To assess the quality of the included studies, we used the
Quality Assessment of Studies of Diagnostic Accuracy
Included in Systematic Reviews (QUADAS-)2 tool [9]. This
tool is designed to assess the quality of primary diagnostic
accuracy studies. It consists of 4 key domains that address
(1) patient selection, (2) index test, (3) reference standard
and (4) flow of patients through the study and timing of the
index tests and reference standard. The domains are assessed
for risk of bias and applicability. The two reviewers (W.P.K.
and J.P.) used this tool to independently evaluate the method-
ological quality of the included studies. Disagreements were
solved by discussion and thus the final report is based upon
consensus of the two reviewers.
Data extraction
Data were extracted using a standardized spreadsheet. Study
design characteristics included the tracer used, injected dose,
possible combination with CT, study population, and number
of included patients. Since pHPT is a biochemical diagnosis
and all patients included were diagnosed with pHPT, there
were no true negative scans and therefore specificity and
NPV were not calculated. The performance of PET was
expressed in sensitivity (total number of glands localized to
the correct quadrant / total number of pathological glands
found during surgery) and PPV (total number of glands local-
ized to the correct quadrant / total number of glands suspicious
for adenomas or hyperplasia). Data regarding MET was cal-
culated using pooled proportion and displayed using forest
plots. Sensitivity was defined as the probability that the local-
ization study correctly identified the pathological gland(s).
PPV was defined as the probability that a patient with a pos-
itive localization study had a pathological gland in that specif-
ic location. If data regarding sensitivity or PPVwas missing in
the selected paper, the author was contacted. Since sensitivity
and PPV were calculated using the aforementioned criteria for
patients with pHPT, the results may differ from the original
papers.
For the studies investigating MET, random-effects models
(REM) were used to pool the data [10]. The REM model was
fit to account for study heterogeneity. The heterogeneity
among studies was tested using the I2 statistic test with a p
value of less than 0.1 for statistical significance [11]. The I2
statistic is expressed in a percentage scale in which 0 %
Fig. 1 Flowchart of study
inclusion
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implies study homogeneity and 100 % indicates that between-
study variance is much larger than within study variance. The
investigated study population could have influenced the diag-
nostic performance, thereby causing heterogeneity, and was
therefore investigated by subgroup-analysis. The studies were
subdivided into 3 groups consisting of patients (1) without
specific selection, (2) with negative or discordant convention-
al imaging, and (3) with a history of previous parathyroid
surgery. Funnel plots were used as a visual tool for investigat-
ing heterogeneity and publication bias [12]. These plots are
scatterplots of the treatment effects estimated from individual
studies against a measure of study size. In the absence of
publication bias, the funnel plots are symmetrical.
Data analysis was performed using StataSE 13 and con-
ducted by a biostatistician specializing in meta-analysis
(I.A.). For this type of study, no formal consent is required.
Results
Literature search
The literature search yielded a total of 1174 unique papers, of
which 41 papers remained eligible after screening of title and
abstract for relevance. After full text review, 24 papers were
included. These were subdivided by radiopharmaceutical: 14
studies investigated 11C-MET, one [11C]2-hydroxy-N,N,N-
trimethylethanamium (11C-CH), six 18F-FDG, one 6-[18F]
fluoro-L-DOPA (18F-DOPA), and three N-[(18F)Fluoromethyl]-
2-hydroxy-N,N-dimethylethanaminium (18F-FCH) [13–36].
Excluded were studies that had fewer than five patients, abstracts
from conferences without available full text, and redundant stud-
ies investigating the same population. The process of study se-
lection is illustrated in Fig. 1. The 14 studies investigating MET
underwent meta-analysis, which included a total of 327 patients
with 364 lesions.
Characteristics of the MET studies
All studies were single-center and included between eight and
29 patients, with the exception of the study by Weber et al.,
which included 102 patients. Four studies had a prospective
design, whereas the rest were conducted retrospectively. Most
studies also involved patients with secondary (sHPT) or ter-
tiary HPT, or patients that did not proceed to surgery (our gold
standard). These patients were excluded from the analysis.
Patients with negative or discordant conventional imaging
were included in three studies, and two other studies specifi-
cally included patients with previous neck surgery. The
injected dose of radioactive tracer varied between 370 and
1100 MBq (10–30 mCi) and scanning started between 0 and
40 min after injection with an additional low-dose CT in ten
studies. The characteristics are listed in Table 2.
Quality assessment of the MET studies
Quality assessment is displayed in Fig. 2 using the QUADAS
2 tool for risk of bias and applicability. Overall, there was a
particularly high risk of bias arising from lack of a reference
standard and heterogeneity in patient selection. Bias related to
the reference standard relates to the fact that a clear definition
of cure was lacking in several of the studies. The reference
standard varied between no mention of follow-up data to doc-
umentation of normocalcemia at 6 months, which is the wide-
ly excepted definition of cure. Since estimates of accuracy are
based on the assumption that the reference standard is 100 %
sensitive and specific, the lack of a clear reference standard
might have resulted in misinterpretation of the accuracy of the
index test. Substantial risk of bias was present since most
studies did not enroll consecutive patients or a random sample
of eligible patients. Moreover, as can be seen in Table 2, only a
proportion of patients included in the studies underwent sur-
gery. (Because of this, some studies were excluded from the
meta-analysis, since they only performed surgery on patients
with a positive scan, potentially overestimating its perfor-
mance.) Concerns regarding applicability were low for the
index test, as the scans were usually conducted according to
a specific protocol within the studies. However, there was
great variability between studies with regard to the PET pro-
tocol in terms of tracer dose, use of additional CT, and timing
of the scan, which raises concerns as to the applicability of the
index test. Patient selection also raises applicability concerns,
since the study populations of patients were variable and could
not entirely be adjusted for via sub-analysis.
Publication bias was investigated using a funnel plot. The
distribution indicates a publication bias of small and most
likely irrelevant studies (Fig. 3).
Accuracy and heterogeneity of the MET studies
Individual and summary estimates of per-quadrant sensitivity
and PPVare shown in Fig. 4a and b. Sensitivity for the detec-
tion of a lesion in the correct quadrant ranged from 44 to 91%,
with a pooled estimate of 77 % (95 % CI 71–84 %).
Subgroup-analysis based on selection of included patients
was performed as well. A total of 9 studies did not specifically
select patients (group 1) and showed a random pooled sensi-
tivity of 78% (95 %CI 70–86%), which was almost the same
as for the three studies that included patients with negative or
inconclusive conventional imaging (group 2) and had a
pooled sensitivity of 81 % (95 % CI 70–91 %). The two
studies that predominantly investigated patients with previous
parathyroid surgery had discrepant outcomeswith sensitivities
of 54 and 84 %. Heterogeneity was overall high with I2 of
51 % (p=0.01) for all 14 studies and moderate between the 2
subgroups (I2 =42 %; p=0.06) (Fig. 4a and b). Pooled PPV
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ranged from 91 to 100 % with a pooled estimate of 98 %
(95 % CI 96–100 %) (Fig. 5).
Other investigated PET tracers
Details about studies investigating other PET tracers are listed
in Table 3. From six studies investigating FDG, three were
from the same author; however, the domain differed. Two of
these included only patients without previous parathyroidec-
tomy—consisting of 17 and 21 patients with pHPT—and ex-
cluded patients with hyperplasia from the results [33, 36].
These studies found sensitivities of 94 and 86 % and PPVs
of 85 and 86 %, respectively. The third included 20 patients
with a history of neck surgery and found a much lower sensi-
tivity and PPV, both 62 % [32]. The three other studies found
even lower sensitivities, varying between 0 and 27 %, al-
though PPVs were consistently high. Notably, none of the 8
scans performed by Sisson et al. showed a focus that could be
attributed to a parathyroid adenoma [35].
Five recent studies published results regarding 18F-FCH;
however, Michaud et al. and Lezaic et al. published two arti-
cles using the same population [28, 29, 37, 38]. The most
recent study of Michaud et al. included 17 patients without
prior neck surgery, divided in 11 patients with pHPT, five with
sHPT, and one lithium-associated [28]. All patients had 18F-
FCH PET-CT because of negative/discordant ultrasound and
123I/99mTc-sestamibi subtraction scintigraphy. Sensitivity per
lesion was up to 94 %. The most recent study of Lezaic et al.
included 43 patients with pHPT and no previous neck surgery
[29]. All patients underwent ultrasound, 99mTc-sestamibi/
pertechnetaat subtraction scintigraphy, SPECT-CT, and 18F-
FCH PET-CT. Sensitivity per lesion of PET-CT was up to
95 %. Kluijfhout et al. conducted 5 scans in patients with
negative conventional imaging and found a sensitivity of
80 % with a PPVof 100 % [27].





Year No. of patients Study population Dose (MBq) CT Time (min)
Total pHPT+ surgery
Braeuning 2015 18 12 Neg/disc imaging 600 yes 20
Hayakawa 2015 23 15 Mixed 441–906 yes 15–34
Chicklore 2014 43 15 Mixed 740 yes 10
Martinez 2014 14 14 Mixed 740 yes 10 and 40
Weber 2013 102 102 Mixed ? yes 20
Chun 2013 16 8 Neg/disc imaging 370–444 yes 30–40
Schalin 2012 21 21 Previous surgery 440 yes 20
Oksuz 2011 8 8 Mixed 700 4/4 15
Weber 2010 33 33 Mixed ? yes 20
Herrmann 2009 41 9 Mixed 430 no 15–20
Tang 2008 30 22 Mixed 555 yes 20
Beggs 2005 51 29 Neg/disc imaging 619 no 15
Otto 2004 30 14 Mixed 900–1100 no 10
Sundin 1996 34 25 Previous surgerya 750 no direct
pHPT primary hyperparathyroidism, Neg negative, Disc discordant
a Previous surgery in 25/34 patients included in the study
Fig. 2 QUADAS 2 tool for risk
of bias and applicability
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Lange-Nolde et al. investigated the performance of 18F-
DOPA [31]. They included eight patients with pHPT. All
had histologically proven adenomas; however, none of the
scans showed any detectable uptake.
Orevi et al. published preliminary results of 11C-CH PET-
CT [30]. They included 40 patients with HPT, of which 20
were diagnosed with pHPT and the latter predominantly with
sHPT. In 24 of 27 patients that underwent surgery so far, there
was concordance between PET result and surgical findings.
There was insufficient data to calculate specific performance
for patients with pHPT; however, the scan was clearly positive
in 37 out of 40 patients.
Discussion
We performed a meta-analysis to investigate the performance
of 11C-MET PET to localize pathological parathyroid
gland(s) in patients with pHPT. Our results show a pooled
sensitivity and PPV for the detection of a pathological para-
thyroid in the correct quadrant of 77 and 98%, respectively. In
subgroup-analysis, we found no difference in sensitivity in
patients without specific selection versus patients with
negative/discordant conventional imaging (78 versus 81 %,
respectively). Among the other investigated tracers in our sys-
tematic review, 18F-FCH seems the most promising with sen-
sitivity ranging from 80–100 % and PPV 89–100 % in three
studies with a total of 37 patients.
Our pooled sensitivity of 77 % is slightly lower than the
pooled sensitivity of 81 % found by Caldarella et al. who
published a meta-analysis regarding 11C-MET PET in 2012
[39]. Since then, new evidence has been published and there
are several major methodological differences between that
study and the current meta-analysis. First, Caldarella et al.
did not solely include patients with pHPT but also with
sHPT. Second, their calculations are based on a per-patient
level: as most surgeons favor MIP to bilateral neck explora-
tion, a per-lesion sensitivity for localization to the correct
quadrant may be more clinically relevant. Identification of
the right quadrant per lesion is more precise, which might
explain our slightly lower pooled sensitivity. Lastly, PPV is
not calculated; instead, the authors presented a detection rate,
defined as percentage of positive scans, without correlating
this to the surgical outcome. In an attempt to examine a more
homogenous group, we included only patients with pHPT.
The domain of the included patients did however still vary
greatly, which is why subgroup-analysis was performed to
examine whether patient domain influenced the accuracy of
11C-MET PET.
In subgroup-analysis, performance of 11C-MET PET in a
mixed patient cohort (group 1; pooled sensitivity 78 %) was
comparable to conventional 99mTC-sestamibi SPECT (sensi-
tivity 79 %), but substantially lower compared to sestamibi
SPECT/CT (sensitivity of 88 %) [40, 41]. Remarkably, the
performance of 11C-MET PET did not decline significantly
when only patients with negative or inconclusive imaging
were included (group 2, pooled sensitivity 81 %). This sug-
gests that 11C-MET PET is relatively most useful in a sub-
stantial amount of cases with negative/discordant convention-
al imaging and could therefore be considered as a suitable
second-line imaging modality.
The ability of 11C-MET PET to detect hyperplastic glands
was lower compared to patients with adenomas. In the largest
study included in our meta-analysis, overall sensitivity was
83 %, versus 33 % for hyperplastic glands [17]. Hyperplastic
glands are often smaller in size and weigh less than adenomas,
both factors that have previously been associated with de-
creased sensitivity [14]. This might also be a contributing rea-
son as to why performance is lower in patients with persistent
pHPTafter previous parathyroid surgery. Schalin et al. included
21 patients with pHPT and persistent disease and found a sen-
sitivity of 44 %, substantially lower than the pooled sensitivity
of 77 % found in this study [19]. Weber et al. also performed a
subgroup-analysis on patients with previous neck surgery, in-
cluding patients after thyroid surgery. Remarkably the sensitiv-
ity in this group was higher compared to the total group (94
versus 83 %). Thyroid tissue reduces the lesion-to-background
ratio due to physiological thyroidal uptake of 11C-MET and
thereby complicates reading of parathyroid scans [22].
Pathological parathyroids that are in a juxtathyroidal location
can therefore cause false negative outcomes [26].
Detection of accumulated 11C-MET can be done at differ-
ent times after injection, and protocols varied in this study
from scanning immediately after injection to scanning
40 min post-injection. Two studies had protocols in which
patients were scanned twice at 10 and 40 min to compare
the effect of timing on diagnostic efficacy [16, 25]. They
found the best parathyroid to background contrast and the best
Fig. 3 Funnel plot of 11C-Methionine studies included in this meta-
analysis. The distribution indicates a publication bias of small and most
likely irrelevant studies
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delineation of hyper-functioning parathyroid after 10 min, al-
though the best parathyroid to thyroid contrast was seen after
40 min. Martinez et al. included the late scan when the 10-min
scan was negative, which resulted in the detection of one
additional positive parathyroid gland in their study. Scans later
than 40 min resulted in insufficient count statistics owing to
the short half-life of 11C-MET (20 min). The short half-life of
11C-METand the complicating labeling procedure is also one
of the biggest limitations ofMET. It requires the center to have
a cyclotron for production of the tracer since transportation
from another facility would take too much time.
Recent publications often used a combination of PET and
CT. Contrast enhancement CT can be useful to differentiate
with lymph nodes and might therefore prevent false positive
Fig. 4 a Forest plot of sensitivity
of all studies. The pooled result is
displayed by the vertical line.
Horizontal lines indicate the 95%
confidence intervals of each
separate study. Size of the square
is directly linked to the number of
patients included in the study. b
Forest plot of sensitivity of
subgroup-analysis depending on
domain of included patients. The
pooled result is displayed by the
vertical line. Horizontal lines
indicate the 95 % confidence
intervals of each separate study.
Size of the square is directly
linked to the number of patients
included in the study. SE
sensitivity, CI confidence interval
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outcomes [42]. However, there is also increasing attention to
the possible risks of extra radiation involved with CT [43].
Several studies also investigated other factors that may affect
the accuracy, such as goiter, thyroiditis, and parathyroid hor-
mone level; however, a separate analysis could not be per-
formed due to insufficient available data. Nevertheless, in
general PET appears to work well even in these settings [17,
26].
The second best investigated tracer is 18F-FDG, which has
the advantage of a significant longer half-time of 110 min,
enabling off-site production. Also, it is by far the most com-
monly used PET radiopharmaceutical and has wide availabil-
ity. These benefits notwithstanding performance varied
greatly between the six studies that have investigated its use
with a sensitivity of 0–94 % and PPV of 62–100 %. Due to
these highly discrepant findings, FDG appears to be a less
useful tracer for the detection of pathological parathyroids.
18F-DOPA, in a limited trial, performed even more poorly.
Using a prospective study design, Lange-Nolde et al. scanned
eight patients with pHPT, each of whom had adenomas de-
tected in the operating room; however, none of the 18F-DOPA
PETscans were positive [31]. More promising seems to be the
use of 11C-CH. A recent prospective study by Orevi et al.
included 40 patients with HPT, and there were 37 choline
positive scans [30]. Although their results are preliminary
and only some of the patients have undergone surgery, these
Fig. 5 Forest plot of positive
predictive value. SE sensitivity,
CI confidence interval
Table 3 Characteristics of studies investigating PET tracers other than 11C-Methionine
Study
First author
Tracer Year No. of patients Dose (MBq) CT Time (min) Sens (%) PPV (%)
Total pHPT+ surgery
Kluijfhout 18F-FCH 2015 5 5 2 MBq/kg yes direct 80 100
Michaud 18F-FCH 2015 17 11 3 MBq/kg yes direct 94 91
Lezaic 18F-FCH 2015 43 43 100 yes 5,60,120 95 97
Orevi 11C-CH 2014 40 ? 370 yes direct ? ?
Lange-Nolde 18F-DOPA 2006 8 8 185–300 no 90 – –
Chicklore 18F-FDG 2014 43 15 400 yes 90 27 100
Neumann 18F-FDG 1997 20 20 185–370 no 45 62 62
Neumann 18F-FDG 1996 21 21 185–370 no 45 86 86
Melon 18F-FDG 1995 7 7 370 no 50 22 100
Sisson 18F-FDG 1994 8 8 370 no ? 0 –
Neumann 18F-FDG 1994 17 17 185–370 no 45 94 85
pHPT primary hyperparathyroidism, Sens sensitivity, PPV positive predictive value
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data suggest that 11C-CH may be an important tracer in
radiographic localization of parathyroid adenomas. The
main disadvantage (similar to 11C-MET) is the short
half-life of 20 min, which obligates on-site production.
This problem has been overcome by the most promising
PET tracer thus far, 18F-FCH, which has a half-life of
110 min. This tracer is frequently used in the diagnostic
work-up and follow-up of patients with prostate cancer
and has, therefore, wide availability. So far, three stud-
ies have published unique data with excellent prelimi-
nary results, even in patients with negative SPECT-CT
[27–29]. The advantage of 18F-FCH PET-CT over
SPECT-CT is the higher spatial resolution, lower radia-
tion burden (around 6 versus 8 mSv), and the substan-
tially shorter scanning time with a single acquisition of
around 10 min, depending on protocol [44].
Besides PET, several other modalities have been
studied for use as a second-line imaging as well.
Computed tomography is available in virtually every
medical center and has been shown to accurately detect
parathyroid adenomas, even in the case of negative con-
ventional imaging [45, 46]. There is increasing attention
to 4D-CT, which can help clinicians differentiate adeno-
mas from other structures in the neck [47]. Performance
has shown to be good, with a sensitivity and PPV of
around 80 and 90 %, respectively, depending on the
investigated population [48, 49]. The major drawback
of this technique, which uses multiple phases, is radia-
tion exposure that can be as high as 26 mSv from a
single scan [50]. MRI can also be used to localize para-
thyroid glands. Evidence remains scarce, but one of the
largest studies so far showed a sensitivity of 82 % with
a PPV of 89 % and a very recent publication also
showed promising results [51, 52]. Considering the
unique benefits of 18F-FCH PET and MRI, a potentially
superior modality would be using the 18F-FCH tracer
and a combined PET MRI scanner. Although no studies
have been published yet, preliminary results from a
pilot-study show excellent results in patients with nega-
tive or discordant conventional imaging [Unpublished
results Kluijfhout et al.].
Our meta-analysis has several limitations. Like any
meta-analysis, its quality is limited by the number and
quality of constituent studies. Each individual study in-
cluded only a small number of patients. As shown by
the QUADAS 2 tool, there was also a substantial risk of
bias arising from variability in patient selection and ref-
erence standard. Moreover, there is concern regarding
applicability as various imaging protocols were used.
The results of this meta-analysis should therefore be
interpreted with caution, and more research, especially
in the form of prospective studies, is needed to confirm
our observations.
Conclusion
To our knowledge, this is the first systematic review investi-
gating all PET tracers that have been used for the detection of
pathological parathyroid glands. The results of our meta-
analysis show that 11C-MET PET has an overall good sensi-
tivity and PPV and may be considered a reliable second-line
imaging modality to enable minimally invasive parathyroid-
ectomy. Our literature review suggests that 18F-FCH PET
may produce even greater accuracy and should be further
investigated using both low-dose CT and MRI for anatomical
correlation.
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